Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Notice of Proposed Sale · 144

Avalyn Pharma Inc.

AVLNNASDAQEQUITYCurrent

Notice of Proposed Sale

Filed Nov 17, 2026Accepted Nov 17, 2026, 4:39 PM ESTFiling CIK 1540171Accession 0001950047-26-011259
Share

Structured filing — 144

primary_doc.xml

Open full document ↗

Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.

Proposed-sale notice

Issuer
Avalyn Pharma Inc.
Issuer CIK
0001540171
SEC file number
001-43251
Phone
2067070340
Person for whose account securities are to be sold
HOWARD LAZARUS
Relationships to issuer
Officer
Street
105 W First Street
City
Boston
State / country code
MA
Postal code
02127

Securities proposed for sale

Securities proposed for sale · 1 reported row
SecurityProposed unitsAggregate market valueUnits outstandingApproximate sale dateExchangeBroker / market maker
Common53,2001,583,232.0044,521,49411/17/2026NASDAQMorgan Stanley Smith Barney LLC Executive Financial Services

Broker / market maker — proposed row 1, entry 1

Name
Morgan Stanley Smith Barney LLC Executive Financial Services
Street
1 New York Plaza
Street (continued)
8th Floor
City
New York
State / country code
NY
Postal code
10004

Acquisition of securities to be sold

Acquisition of securities to be sold · 1 reported row
SecurityAcquiredNature of acquisitionAcquired fromAmount acquiredGift transactionPayment dateNature of payment
Common11/17/2026Exercise of Stock OptionsIssuer53,200N11/17/2026Cash

Prior-sale reporting

Nothing to report for the preceding three months
Y

Remarks

The securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale.

Notice signature

Notice date
11/17/2026
Signed
/s/ Howard Lazarus
Plan adoption dates
07/30/2026

Company context

Avalyn aims to transform the treatment paradigm for pulmonary fibrosis and other serious, rare respiratory diseases. The company is advancing optimized inhaled formulations of established antifibrotic medicines designed to deliver drug directly to the lungs, enhance local efficacy, and reduce systemic side effects. Avalyn’s AP01 program is an optimized inhaled formulation of pirfenidone currently being evaluated in MIST, a global Phase 2b clinical trial in patients with progressive pulmonary fibrosis (PPF). AP01 has demonstrated encouraging safety and clinical activity across Phase 1b and an ongoing, multi-year open-label extension trial, with long-term data supporting the potential to preserve lung function while improving tolerability relative to historical oral pirfenidone. Avalyn’s AP02 program is an optimized inhaled formulation of nintedanib currently being evaluated in AURA, a global Phase 2 clinical trial in patients with idiopathic pulmonary fibrosis (IPF). Avalyn is also advancing AP03, an inhaled fixed-dose combination of pirfenidone and nintedanib, designed to deliver multiple antifibrotic mechanisms through a single lung-targeted platform. By leveraging its proprietary drug-device approach and deep expertise in rare respiratory disease development, Avalyn aims to establish a new standard of care in pulmonary fibrosis through inhaled, lung-targeted therapies. For more information, please visit avalynpharma.com and follow the company on LinkedIn.

Current securities

Recent company filings

  1. 4 filingNov 12, 2026
  2. 10-Q filingNov 12, 2026
  3. Results of Operations and Financial ConditionNov 12, 2026
  4. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsSep 16, 2026
  5. 10-Q filingAug 12, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.